340B pilot, FDA shakeup, and the PBM biosimilar play
Supply Chain Pulse — 2026-05-13
HRSA is floating a 340B rebate pilot that could fundamentally reshape how safety-net hospitals access discounted drugs—while providers are pushing back hard and pharma companies are calling it the only path to program accountability. Meanwhile, FDA Commissioner Marty Makary's abrupt resignation after less than four months creates regulatory uncertainty just as PBMs double down on private-label biosimilars to squeeze more margin from specialty drug spending. Between policy upheaval and profit motives, supply chain leaders need to prep for a more complex—and potentially more expensive—drug procurement landscape.
Quick Hits
- Air cargo spot rates jump 30% in April on supply constraints, not fuel costs (Supply Chain Dive)
- 2026 Medtec conference to explore surgical robotics supply chain innovations (GDELT)
HRSA floats 340B rebate pilot amid fierce industry pushback
The agency is considering a rebate model for the 340B Drug Pricing Program that would require participating hospitals to pay upfront for drugs and receive discounts later—a departure from the current front-end discount structure. Hospitals argue this would strain cash flow and administrative resources, while drugmakers see it as the only way to restore program oversight and prevent duplicate discounts. For supply chain teams, this could mean major changes to drug procurement workflows and working capital management if the pilot moves forward.
FDA Commissioner Makary resigns after four months, creating regulatory uncertainty
Marty Makary's sudden departure as FDA Commissioner, with reports suggesting he was pushed out by the White House, leaves the agency under acting leadership during critical device approval cycles and drug shortage responses. Acting Commissioner Diamantas takes over as the agency navigates ongoing supply chain disruptions and an increasingly complex regulatory environment. Expect potential delays in guidance updates and policy decisions while leadership stabilizes.
PBMs push private-label biosimilars to boost margins
Major healthcare conglomerates with insurance and PBM arms are increasingly favoring biosimilars manufactured by their overseas subsidiaries, creating potential conflicts of interest in formulary decisions. This trend could limit hospital access to certain biosimilar brands and concentrate market power among a few integrated players. Supply chain leaders should monitor formulary changes closely and evaluate whether preferred biosimilars truly offer the best clinical and economic value.
AI transforms medtech sales from cold calls to data-driven targeting
Medical device companies are replacing traditional sales approaches with AI-powered platforms that analyze hospital purchasing patterns, clinical outcomes, and financial data to identify the best prospects and timing for product pitches. This shift means supply chain teams can expect more sophisticated—and potentially more persuasive—vendor presentations backed by facility-specific data. The upside: better-informed discussions about ROI and clinical fit.
AHA launches $12M accelerator to scale hospital tech adoption
The American Hospital Association and West Health Institute are funding a program to help hospitals implement and scale technology-enabled solutions that have already proven clinical value elsewhere. The initiative targets the persistent gap between promising pilot projects and system-wide deployment—a familiar pain point for supply chain leaders managing innovation portfolios. Applications open for health systems ready to move beyond proof-of-concept.
Source: Healthcare Purchasing News
You're receiving this because you subscribed to Supply Chain Pulse, a daily brief for healthcare supply chain professionals. Unsubscribe